Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Background. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of our study was...

Full description

Bibliographic Details
Main Authors:	Barbara Ruaro, Andrea Salotti, Nicolò Reccardini, Stefano Kette, Beatrice Da Re, Salvatore Nicolosi, Umberto Zuccon, Marco Confalonieri, Lucrezia Mondini, Riccardo Pozzan, Michael Hughes, Paola Confalonieri, Francesco Salton
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Pharmaceuticals
Subjects:	idiopathic pulmonary fibrosis (IPF) interstitial pneumonia interstitial lung disease (ILD) Nintedanib (NTD) pulmonary function tests (PFTs) high-resolution computed tomography (HRTC)
Online Access:	https://www.mdpi.com/1424-8247/17/1/119

Similar Items

Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy
by: Barbara Ruaro, et al.
Published: (2023-02-01)

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
by: Barbara Ruaro, et al.
Published: (2022-08-01)

High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients
by: Barbara Ruaro, et al.
Published: (2021-10-01)

Editorial: Pulmonary fibrosis: One manifestation, various diseases
by: Barbara Ruaro, et al.
Published: (2022-10-01)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
by: Toshiyuki Sumi, et al.
Published: (2021-03-01)

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
by: Maria Boutel, et al.
Published: (2023-03-01)

Nintedanib in systemic sclerosis treatment: a case report
by: Maysoun Kudsi, et al.
Published: (2024-02-01)

Transbronchial lung cryobiopsy and pulmonary fibrosis: A never-ending story?
by: Barbara Ruaro, et al.
Published: (2023-04-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Differential Transcriptomic Signatures of Small Airway Cell Cultures Derived from IPF and COVID-19-Induced Exacerbation of Interstitial Lung Disease
by: Katie Uhl, et al.
Published: (2023-10-01)

Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases
by: Minna Mononen, et al.
Published: (2022-08-01)

Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients
by: Benjamin Bondue, et al.
Published: (2019-01-01)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
by: Ulrike Schmid, et al.
Published: (2021-07-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Nintedanib in chronic fibrosing interstitial lung diseases. A case series
by: Raquel García Sevila, et al.
Published: (2024-04-01)

Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study
by: Kyung-In Joung, et al.
Published: (2023-03-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features
by: Federica Galioto, et al.
Published: (2020-07-01)

Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosisResearch in context
by: Theresia A. Mikolasch, et al.
Published: (2023-01-01)

Smoking Related Interstitial Lung Disease - High Resolution Computed Tomography (HRCT) findings in 40 smokers
by: Youssriah Yahia Sabri, et al.
Published: (2014-06-01)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-11-01)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
by: Andreas Guenther, et al.
Published: (2018-07-01)

What is new in the treatment of interstitial lung diseases
by: Vasilina Sotiropoulou, et al.
Published: (2023-06-01)

The impact of respiratory reactance in oscillometry on survival in patients with idiopathic pulmonary fibrosis
by: Tatsuru Ishikawa, et al.
Published: (2024-01-01)

Discrimination between NSIP- and IPF-Derived Fibroblasts Based on Multi-Parameter Characterization of Their Growth, Morphology and Physic-Chemical Properties
by: Barbara Orzechowska, et al.
Published: (2022-02-01)

High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?
by: Barbara Ruaro, et al.
Published: (2021-12-01)

The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
by: Aulia Rahman Ardan, et al.
Published: (2023-11-01)

Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
by: Kazuki Nakashima, et al.
Published: (2021-01-01)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
by: KM Roach, et al.
Published: (2021-10-01)

Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
by: Yoichiro Aoshima, et al.
Published: (2021-02-01)

Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
by: Marco Sebastiani, et al.
Published: (2023-11-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break
by: Paraskevi Kirgou, et al.
Published: (2022-08-01)

Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-08-01)

A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study
by: Sebastian Majewski, et al.
Published: (2023-07-01)

Clinical Characterization and Predictive Factors for Progression in a Cohort of Patients with Interstitial Lung Disease and Features of Autoimmunity: The Need for a Revision of IPAF Classification Criteria
by: Francesco Bozzao, et al.
Published: (2023-04-01)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01)

Historical eye on IPF: a cohort study redefining the mortality scenario
by: Sara Tomassetti, et al.
Published: (2023-06-01)